New Method Maps the Brain's Blood Vessel Surface Proteins with Unprecedented Precision

The blood-brain barrier (BBB) is maintained by highly polarized brain endothelial cells whose luminal (blood-facing) and abluminal (brain-facing) surfaces perform distinct and critical functions. The luminal surface senses circulating signals, regulates immune trafficking, controls vascular permeability, and supports a specialized glycocalyx. Despite its importance, prior proteomic studies lacked the spatial resolution to cleanly separate luminal from abluminal proteins, limiting understanding of endothelial polarity and surface biology in vivo.

To address this gap, researchers at Stanford developed Luminal Cerebrovascular Proteomics, a step-by-step in vivo protocol published in Bio-Protocol. The method uses a peristaltic pump to perfuse Sulfo-NHS-biotin — a membrane-impermeable biotinylation reagent — directly through the vasculature of anesthetized C57BL/6J mice. Because the reagent cannot cross cell membranes, it covalently labels only proteins exposed on the luminal surface. A Tris-PBS quench step stops the reaction, and the brain is then processed for microvessel isolation using dextran-based density centrifugation.

Isolated microvessels are lysed in RIPA buffer, and biotinylated proteins are captured using Pierce streptavidin magnetic beads. Proteins are then digested on-bead using a urea-based buffer with trypsin/LysC, and the resulting peptides are analyzed by liquid chromatography–tandem mass spectrometry (LC-MS/MS). The microvessel isolation step is a key innovation, substantially reducing background contamination from non-vascular brain tissue and improving signal-to-noise for true luminal proteins.

Using this approach, the team robustly identified over 1,000 luminally localized proteins, the majority annotated as cell surface proteins involved in transport, adhesion, signaling, communication, and extracellular matrix organization. Enrichment of canonical luminal markers — such as transporters and adhesion molecules — was substantially improved compared to conventional whole-vascular proteomics. The method was also applied to uncover aging-related changes in luminal endothelial surface protein composition, demonstrating its utility for studying how the BBB changes with age and disease, including findings related to glycocalyx dysregulation published in Nature (2025).

The protocol is scalable, adaptable to diverse biological contexts, and directly applicable to identifying therapeutic targets, novel CNS drug delivery receptors, biomarkers of vascular dysfunction, and disease-associated surface alterations. Comparing luminal-specific versus whole-surface vascular proteomes also provides a powerful strategy to resolve molecular distinctions between endothelial compartments and deepen understanding of apicobasal polarity in vivo.